Steven's cancer was tough to fight. Let's change that.

Desmoplastic small round cell tumor (DSRCT) is a microscopic disease. Because it’s small and pervasive, it’s difficult to target with chemotherapy and radiation, meaning some tumors may be left behind after these traditional treatments. Those tumors continue to multiply, and relapse is common.

That’s why the Steven Vanover Foundation is helping to fund a clinical trial at Memorial Sloan Kettering Cancer Center that studies alternative treatment options for those with DSRCT. The protocol that Dr. Shakeel Modak is testing involves injecting an antibody that targets the microscopic tumors in order to prevent relapse. This kind of science could literally help save the lives of those few young adults like Steven who get such a rare cancer diagnosis in the near future.

To date, your gifts to the Steven Vanover Foundation have helped us fund nearly $300,000 toward these research efforts.

We are beyond grateful for every single donor because this is something that could have made a difference to Steven had it been available five years ago. It’s the only research of its kind that could provide alternative options for DSRCT patients, but it has also been found to improve relapse rates in patients with other types of rare cancers and diseases. So in a way, it’s making a bigger impact than we could have ever imagined.

We highly encourage every supporter to watch the video and learn more about this disease and the strides that are being made.

As we always say, we love to support cancer research of any kind, but there are so many rare cancers like sarcoma that don’t get the research dollars it takes to study and understand these diseases. So together, you and all of our supporters are helping to make a significant impact for those who feel there’s not much hope.

Special thanks to Memorial Sloan Kettering Cancer Center for developing the video below. Enjoy!

You can make a contribution today by visiting our donation page.